FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns
Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. The FDA slapped a clinical hold on a phase 1b plaque psoriasis trial after testicular toxicity was reported in dogs.
